EyePoint Pharmaceuticals. has been granted a patent for methods to treat Vascular Leak Syndrome and prevent cancer metastasis. The patent includes a specific method involving an HPTPß-ECD binding agent and anti-cancer agents to address vascular leakage associated with various diseases. GlobalData’s report on EyePoint Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on EyePoint Pharmaceuticals, NSAID cancer drugs was a key innovation area identified from patents. EyePoint Pharmaceuticals's grant share as of June 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Methods for treating vascular leak syndrome and cancer
The granted patent US12043664B2 outlines a novel method for treating cancer by administering a specific binding agent known as HPTPß-ECD, particularly the agent R15E6 or its humanized variants, alongside one or more anti-cancer agents that are known to induce vascular leak syndrome. The method aims to reduce vascular leak syndrome in patients, which can be a side effect of certain cancer treatments. The claims specify that this approach not only mitigates the adverse effects associated with vascular leak syndrome but also potentially reduces cancer metastasis and stabilizes the vasculature in the subject. The administration of the HPTPß-ECD binding agent can be performed via intravenous or subcutaneous injection.
Additionally, the patent details various forms of the HPTPß-ECD binding agent, including multi-specific and bispecific antibodies, and identifies potential anti-cancer agents such as IL-2. The method is applicable to a range of cancers, including leukemia, lymphoma, astrocytoma, glioma, carcinoma, and sarcoma. Importantly, the claims allow for the simultaneous or sequential administration of the HPTPß-ECD binding agent and the anti-cancer agents, providing flexibility in treatment protocols. This innovative approach may enhance the efficacy of cancer therapies while addressing the complications associated with vascular leak syndrome.
To know more about GlobalData’s detailed insights on EyePoint Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
